



# LUND UNIVERSITY

## The Gold Standard Programme: smoking cessation interventions for disadvantaged smokers are effective in a real-life setting

Neumann, Tim; Rasmussen, Mette; Ghith, Nermin; Heitmann, Berit L.; Tønnesen, Hanne

*Published in:*  
Tobacco Control

*DOI:*  
[10.1136/tobaccocontrol-2011-050194](https://doi.org/10.1136/tobaccocontrol-2011-050194)

2013

[Link to publication](#)

### *Citation for published version (APA):*

Neumann, T., Rasmussen, M., Ghith, N., Heitmann, B. L., & Tønnesen, H. (2013). The Gold Standard Programme: smoking cessation interventions for disadvantaged smokers are effective in a real-life setting. *Tobacco Control*, 22(6), e9. <https://doi.org/10.1136/tobaccocontrol-2011-050194>

*Total number of authors:*  
5

### **General rights**

Unless other specific re-use rights are stated the following general rights apply:  
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00



OPEN ACCESS

# The Gold Standard Programme: smoking cessation interventions for disadvantaged smokers are effective in a real-life setting

Tim Neumann,<sup>1,2</sup> Mette Rasmussen,<sup>1</sup> Nermin Ghith,<sup>1,2</sup> Berit L Heitmann,<sup>3</sup>  
Hanne Tønnesen<sup>1,2</sup>

<sup>1</sup>WHO CC, Clinical Health Promotion Centre, Bispebjerg University Hospital, Copenhagen, Denmark

<sup>2</sup>Clinical Health Promotion Centre, Department of Health Sciences, Lund University, Malmö, Sweden

<sup>3</sup>Research Unit for Dietary Studies, Institute of Preventive Medicine, Bispebjerg University Hospital, Copenhagen, Denmark

## Correspondence to

Dr Tim Neumann, Clinical Health Promotion Centre, Department of Health Sciences, Lund University, SUS, Entrance 108, SE-205 02, Malmö, Sweden; [tim.neumann@charite.de](mailto:tim.neumann@charite.de)

This paper has been presented in part at the 19th International Conference on Health Promoting Hospitals & Health Services, 2011, Turku, Finland.

Received 19 August 2011  
Accepted 20 May 2012

Published Online First  
16 June 2012

## ABSTRACT

**Objectives** To evaluate the real-life effect of an evidence-based Gold Standard Programme (GSP) for smoking cessation interventions in disadvantaged patients and to identify modifiable factors that consistently produce the highest abstinence rates.

**Design** Observational prospective cohort study.

**Setting** GSPs in pharmacies, hospitals and communities in Denmark, reporting to the national Smoking Cessation Database.

**Participants** Disadvantaged patients, defined as patients with a lower level of education and those receiving unemployment benefits.

**Interventions** 6-week manualised GSP smoking cessation interventions performed by certified staff.

**Main outcome measures** 6 months of continuous abstinence, response rate: 80%.

**Results** Continuous abstinence of the 16 377 responders was 34% (of all 20 588 smokers: 27%). Continuous abstinence was lower in 5738 smokers with a lower educational level (30% of responders and 23% of all) and in 840 unemployed (27% of responders and 19% of all). In respect to modifiable factors, continuous abstinence was found more often after programmes in one-on-one formats (vs group formats) among patients with a lower educational level, 34% (vs 25%,  $p=0.037$ ), or among unemployed, 35% (vs 24%,  $p=0.099$ ). The variable 'format' stayed in the final model of multivariable analyses in patients with a lower educational level, OR=1.31 (95% CI 1.05 to 1.63).

**Conclusions** Although continuous abstinence was lower among disadvantaged smokers, the absolute difference was small. If the programme had been as effective in disadvantaged as in non-disadvantaged groups, there would have been an extra 46 or 8 quitters annually, respectively. Promoting individual interventions among those with a low education may increase the effectiveness of GSP.

## INTRODUCTION

Smoking rates are higher among individuals from lower socioeconomic groups. Access to preventive health services, such as smoking cessation programmes, is limited, and the success rate is reported to be even smaller.<sup>1-4</sup> The efficacy of smoking cessation interventions in research settings has been described in randomised clinical trials.<sup>4-10</sup> There have been few studies of the effectiveness of interventions implemented in real-life settings, thus results from efficacy trials might not reflect real-life conditions.<sup>11 12</sup>

The Danish Smoking Cessation Database (SCDB-DK) offers a unique opportunity to analyse the effectiveness of real-life smoking cessation interventions.<sup>13 14</sup> This high-quality clinical database combines comprehensive information on 67 000 smoking interventions taking place at the smoking cessation intervention units. Smokers have been included from 2001 and are followed up to 6 months after the intervention. The SCDB-DK reflects a diversity of settings, formats and organisations. The main programme is the Gold Standard Programme (GSP).<sup>15-17</sup> In order to further address smoking-related inequality in healthcare, we must know which programmes are most effective for the disadvantaged. The data set also allowed exploration of factors that might be modified in order to increase continuous abstinence among disadvantaged groups, such as the programme setting payment and modality, as well as more traditional factors such as age or gender which might affect outcome but are not modifiable. We were not aware of any current literature addressing these issues. In general, there is some evidence that group programmes are more effective<sup>7 18</sup> and that incentives have a short effect but no consistent long-term effect.<sup>19</sup> With regard to geography, Denmark is a very small country with a good infrastructure, and the capital is not far from the regions. The Danes travel back and forth between regions every day; therefore, another region for smoking cessation intervention could easily be chosen. Therefore, the geographical region was considered a potentially modifiable factor, although this might not always be the case.

Thus, the aim of this study was to identify the programme, setting, payment modality and geographic region with the highest rates of continuous abstinence in disadvantaged patients.

## METHODS

### Design

This was an observational prospective cohort study using data from a national registry (Smoking Cessation Database).

### Setting

During the study period, smoking cessation programmes were offered in all five Danish regions by more than 350 units in hospitals and primary care facilities, including pharmacies, municipality facilities and others.

### Participants


From the beginning of 2001 to the summer of 2011, approximately 67 000 smoking cessation



Open Access  
Scan to access more  
free content

## Research paper

**Figure 1** Patient flow. FU, follow-up; GSP, Gold Standard Smoking Cessation Programme; SCI, smoking cessation intervention.



interventions were registered in the Smoking Cessation Databank. Informed consent was obtained. From 2006, registration was performed using a unique 10 digit personal identification number (PIN), and 34 551 interventions were registered with a PIN at the end of January 2011. The PIN can be used to control for doublets. Individuals, who registered in the Smoking Cessation Database, were at least 18 years old, and participated in the GSP in Denmark were included. Patients younger than 18 years (411 patients); patients from Greenland (37 patients); patients without information on gender, age and smoking cessation unit (53 patients); patients with <7-month follow-up (1723 patients) and patients attending interventions other than the GSP (2522 patients) were excluded. Thereby, 29 805 smoking cessation interventions according to GSP were considered. Some smoking cessation units did not systematically follow their patients up to 6 months. Patients in those units were not included in the analysis of the primary outcome (trial profile: figure 1). Of the 21 516 databank entries finally included, seven were double entries and 921 were entries referring to courses of patients attending a programme more than one time (two to seven times). Therefore, 20 588 patients were finally included.

### Intervention

The GSP has been the standard intervention in Denmark since 2001. It was developed with the guidance of the National Cancer Institute, which trained the Stop Smoking Centre.<sup>20</sup> The programme consisted of manual-based teaching sessions together with nicotine replacement therapy.<sup>13 14 20</sup> It consisted of five meetings over 6 weeks, with a clearly structured patient education programme, including a motivational conversation at the beginning, reflections on benefits and costs of continuous smoking versus cessation, date of cessation, teaching and training about risk situations and relapse prevention, withdrawal symptoms and medical support, and planning for the future. Nicotine replacement therapy was provided and adjusted to smoking severity, according to the Fagerström test<sup>21</sup> score, the number of cigarettes (or gram of tobacco when smoking pipes or cigars) and patient preferences. The patients were free to choose different kinds of nicotine products and change their minds during the programme. A hotline was available during daytime hours on working days. GSP was delivered either in a group or in an individual format. The group size varied, with the median being 12 registered participants (range 2–26 participants). The allocation of a single patient to the group or individual

**Table 1** Continuous abstinence rates; OR and 95% CI for the univariate, adjusted analysis and for the final multivariable model

Variables	Lower educational level			Unemployment		
	OR univariate (95% CI)	Adjusted OR (95% CI)	Final adjusted OR (95% CI)	OR univariate (95% CI)	Adjusted OR (95% CI)	Final adjusted OR (95% CI)
Capital vs other regions	0.88 (0.78 to 1.00)	0.95 (0.83 to 1.11)		1.11 (0.77 to 1.59)	1.39 (0.90 to 2.15)	
Setting						
Pharmacy vs other	1.08 (0.93 to 1.24)	0.99 (0.84 to 1.17)		0.89 (0.58 to 1.37)	0.85 (0.52 to 1.41)	
Hospital vs other	0.97 (0.79 to 1.19)	1.01 (0.79 to 1.30)		0.64 (0.39 to 1.07)	0.57 (0.30 to 1.09)	
Individual format vs other	1.25 (1.01 to 1.54)	1.30 (1.03 to 1.63)	1.31 (1.05 to 1.63)	1.56 (0.92 to 2.66)	2.02 (1.07 to 3.79)	
Free medication for <5 weeks	1.14 (0.93 to 1.40)	1.17 (0.92 to 1.48)		0.64 (0.34 to 1.17)	0.78 (0.38 to 1.62)	
Men vs women	1.18 (1.03 to 1.34)	1.26 (1.09 to 1.45)	1.25 (1.09 to 1.43)	1.23 (0.85 to 1.79)	1.39 (0.92 to 2.10)	
Age, each 10 years	1.07 (1.02 to 1.12)	1.03 (0.97 to 1.09)		1.02 (0.89 to 1.18)	0.99 (0.80 to 1.22)	
Pack-year, each 10 years	0.96 (0.93 to 0.99)	1.00 (0.95 to 1.05)		0.93 (0.85 to 1.01)	0.95 (0.82 to 1.11)	
Fagerström, each point	0.88 (0.86 to 0.91)	0.89 (0.86 to 0.92)	0.88 (0.86 to 0.92)	0.89 (0.81 to 0.96)	0.92 (0.82 to 1.03)	0.89 (0.82 to 0.98)
Earlier attempts						
1–3/missing vs no attempts	1.06 (0.93 to 1.21)	0.98 (0.85 to 1.13)		1.19 (0.81 to 1.73)	1.06 (0.71 to 1.609)	
>3 attempts vs no attempt	0.99 (0.78 to 1.27)	0.83 (0.64 to 1.09)		1.73 (0.90 to 3.31)	1.43 (0.70 to 2.93)	
Living with smoker	0.94 (0.82 to 1.08)	1.01 (0.88 to 1.16)		1.10 (0.76 to 1.61)	1.49 (0.98 to 2.26)	
Compliant with the programme	3.32 (2.86 to 3.86)	3.26 (2.80 to 3.80)	3.30 (2.84 to 3.84)	4.60 (3.05 to 6.95)	4.59 (2.99 to 7.05)	4.58 (3.01 to 6.96)
Professional recommendation	0.78 (0.69 to 0.89)	0.79 (0.69 to 0.91)	0.80 (0.70 to 0.92)	0.70 (0.49 to 1.02)	0.91 (0.60 to 1.37)	

**Table 2** Characteristics of all patients with low and high education and their continuous abstinence (given as % of all and of the responders, respectively)

	Low education			High education		
	Characteristics n (%)	Continuous abstinence (%)		Characteristics n (%)	Continuous abstinence (%)	
		All	Responders		All	Responders
All	5738 (100)	23	30	14 850 (100)	28	35
Setting						
Hospital/midwifery	686 (12)	22	29	1613 (11)	30	36
Pharmacies	1677 (29)	24	31	3537 (24)	30	37
Municipality/county	3320 (58)	22	29	9571 (64)	27	34
Other	55 (1)			129 (1)		
Format						
Individual	601 (10)	25	34	1240 (8)	32	40
Group	5106 (89)	22	29	13 536 (91)	28	34
Other	31 (1)			74 (0)		
Medication for free						
No free medication	3135 (55)	23	30	7778 (52)	30	36
Free medication for a few days	1979 (34)	21	28	5806 (39)	26	34
Free medication for <5 weeks	523 (9)	23	31	1065 (7)	27	33
Free medication for 5 weeks	101 (2)	30	41	201 (1)	33	39
Region						
Living in the capital	2072 (36)	21	28	6347 (43)	26	33
Living in other regions	3666 (64)	24	31	8503 (57)	30	36
Midtjylland	1207 (21)	25	31	2860 (19)	30	36
Nordjylland	275 (5)	23	30	539 (4)	31	37
Sjælland	891 (16)	24	31	2152 (14)	29	35
Syddanmark	1293 (23)	24	30	2952 (20)	30	36
Gender						
Male	2221 (39)	24	32	5715 (38)	31	38
Female	3517 (61)	22	28	9135 (62)	27	33
Age (years)						
18–39	1756 (31)	18	27	3588 (24)	26	34
40–49	1237 (22)	24	31	3845 (26)	28	34
50–59	1359 (24)	24	30	4007 (27)	28	35
59–98	1386 (24)	26	32	3410 (23)	31	37
Smoking						
0–20 pack-years	2301 (40)	23	31	5515 (37)	30	39
>20 pack-years	3437 (60)	23	29	9335 (63)	27	33
Fagerström 1–4 points	1968 (34)	28	36	5838 (39)	33	40
Fagerström 5–10 points	3770 (66)	20	26	9012 (61)	25	32
0 to <10 cigarettes per day	487 (8)	26	35	1328 (9)	36	45
10 to <20	1896 (33)	26	34	5317 (36)	30	37
20 to <30	2415 (42)	22	28	6118 (41)	26	32
30 to <40	647 (11)	17	23	1460 (10)	24	30
40+	293 (5)	18	24	627 (4)	23	29
Compliance with programme						
Compliant	3200 (56)	32	39	8970 (60)	37	44
Not compliant	2418 (42)	11	15	5588 (38)	14	18
Missing information	120 (2)	25	33	292 (2)	29	39
Living with a smoker						
Yes	2129 (37)	22	29	4910 (33)	28	34
No	3568 (62)	23	30	9825 (66)	29	36
Missing information	41 (1)	29	44	115 (1)	30	36
Attempts to quit						
Never attempting to quit	2516 (44)	22	29	5535 (37)	28	34
1–3	2724 (47)	23	30	7506 (51)	28	34
>3	438 (8)	23	29	1488 (10)	33	41
Missing information	60 (1)	22	30	321 (2)	23	32
Professional recommendation						
Yes	3345 (58)	21	28	8113 (55)	27	33
No	2393 (42)	25	33	6737 (45)	30	37
Education						
Low level	5738 (100)	23	30			
High level				14 082 (95)	29	35
Missing information				768 (5)	21	28

Continued

Table 2 Continued

	Low education			High education		
	Characteristics n (%)	Continuous abstinence (%)		Characteristics n (%)	Continuous abstinence (%)	
		All	Responders		All	Responders
Unemployment						
Unemployed	371 (6)	16	24	469 (3)	22	29
Not unemployed	5282 (92)	23	30	13 951 (94)	29	35
Missing information	85 (1)	21	31	430 (3)	23	31

programme was at the discretion of the smoking cessation units or the instructors, respectively. The programme was usually offered free of charge. Of the 20 588 patients, 19 185 (93%) received the course for free. Some patients received free medication, while others had to pay themselves.

According to the standard operating procedures defined by the Steering Committee, compliance was defined as attendance of 75% or more of the scheduled meetings.

### Measures (including outcome and independent variables)

#### Outcomes

The primary outcome was continuous abstinence, defined as not smoking at all from the end of the programme to the 6-month follow-up, as reported in a telephone interview after 6 months  $\pm$  1 month. Four attempts were made to reach the patient, and at least one attempt had to be in the evening.

#### Other variables

For every patient, the smoking cessation programme, the specific modifications (individual vs group format), the region (Capital of Copenhagen, Midtjylland, Nordjylland, Sjælland, Syddanmark), the payment modality (no free medication, free medication for a few days, free medication for <5 weeks or 5-week medication free of charge) and the setting (hospitals, pharmacies and county or municipality) were documented categorically. If there were missing data, for the purpose of the multivariable analyses, dummy variables were formed and the missing variables were summarised as shown in the first column of table 1.

The continuous variables such as age, smoking (cigarettes per day, pack-years (years of smoking  $\times$  cigarettes per day divided by 20)) and Fagerström Test for Nicotine dependence<sup>21</sup> were categorised as shown in tables 2 and 3.

Accordingly, quit attempts (never, one to three attempts or at least three attempts or missing information), living with a smoker (vs not living with a smoker or missing information), compliance (attendance of 75% or more of the scheduled meetings), non-compliant with programme (<75%) or missing information on compliance were documented for every patient. All patients were asked whether they received a recommendation from a health professional (eg, doctor, nurse, midwife). There was no difference made between those with no professional recommendation and those not responding to the question concerning professional recommendation.

Lower educational level was defined as no education except school (up to 12 years) or only short work-related courses in contrast to all other levels of education. Unemployment was defined as being available for the labour market and receiving unemployment benefits from the state, the municipalities, insurance or the unions. People at home, retired patients or patients in school were not included in this group; the proportion of patients without information on unemployment and education (4% and 3%, respectively (tables 2 and 3)) was considered small and acceptable for a real-life study.

### Statistical analysis

Existing data were analysed and reported, including missing data, loss of follow-up and sensitivity analyses according to the STROBE<sup>22</sup> recommendations. First, a general description of the sample was given together with a description of the non-responders and the responders. Then, continuous abstinence was reported based on the patients' responses. Most randomised studies addressing the effect of smoking cessation intervention usually report according to the Russell Standards,<sup>23</sup> which assume that it is likely that non-responders have relapsed. Therefore, continuous abstinence was also reported in our study, assuming that non-responders had relapsed.

The estimate of the expected annual number of extra quitters was calculated by multiplying the absolute differences in continuous abstinence rate with the number of the responding patients in this subgroup and by dividing it with the number of years of observation (5 years).

The continuous variables mentioned above were used in the multivariable analyses. Age, pack-years and cigarettes per day were included in steps of 10 (years or cigarettes).

The  $\chi^2$  test or exact methods were used in the analysis of categorical data. A two-sided p value of <0.05 was regarded as significant. The non-parametric Mann-Whitney U test for the comparison of continuous or almost continuous variables was used. Multivariable logistic regression analyses and analyses of variance were used to test for differences in continuous abstinence. Statistical significances of possible predictors of continuous abstinence were compared by calculating the OR and the corresponding 95% CIs. Multiple logistic regression analyses were performed by entering all predictors together, followed by a stepwise backward procedure  $p(\text{in}) < 0.10$ .

Dummy variables were formed for the variables as outlined in table 1 for the purpose of multivariable analysis (eg, capital vs regions, individual programme format, payment modality, living with a smoker, compliance, etc). The items 'other' or 'missing' were added to the bigger group. These numbers were considered as small and acceptable for a real-life study.

All statistical calculations were done with PASW V.18 (IBM Corporation).

### RESULTS

The analysis at 6 months for continuous abstinence included both the 16 377 responders (80%) and the 20% of non-responders (4211 patients). As shown in table 4, responding patients differ mainly with respect to age and compliance from non-responding patients. Non-responders were 3 years younger (median 47.3 vs 50.4 years,  $p < 0.001$ ). Patients compliant with the programme were more likely to respond: proportion of non-responders were lower among compliant patients compared to non-compliant patients (16% vs 27%,  $p < 0.001$ ). Rates of non-responding were 23% for those with a lower educational level and 28% for the unemployed. The proportion of non-responders

**Table 3** Characteristics of the unemployed and not unemployed patients and their continuous abstinence (given as % of all and of the responders, respectively)

	Unemployed			Not unemployed		
	Characteristics n (%)	Continuous abstinence (%)		Characteristics n (%)	Continuous abstinence (%)	
		All	Responders		All	Responders
All	840 (100)	19	27	19 748 (100)	27	34
Setting						
Hospital/midwifery	145 (17)	17	21	2154 (11)	28	35
Pharmacies	219 (26)	19	27	4995 (25)	29	36
Municipality/county	473 (56)	21	29	12 418 (63)	26	33
Other	3 (0)			181 (1)		
Format						
Individual	99 (12)	24	35	1742 (9)	30	38
Group	734 (87)	19	26	17 908 (91)	27	33
Other	7 (1)			98 (0)		
Medication for free						
No free medication	444 (53)	20	29	10 469 (53)	28	35
Free medication for a few days	295 (35)	20	27	7490 (38)	25	33
Free medication for <5 weeks	92 (11)	12	17	1496 (8)	27	33
Free medication for 5 weeks	9 (1)	33	38	293 (1)	32	40
Region						
Living in the capital	337 (40)	21	28	8082 (41)	25	32
Living in other regions	503 (60)	18	26	11 666 (59)	28	35
Midtjylland	208 (25)	20	27	3859 (20)	29	35
Nordjylland	41 (5)	22	29	773 (4)	29	35
Sjælland	113 (13)	18	26	2930 (15)	28	34
Syddanmark	141 (17)	16	24	4104 (21)	28	35
Gender						
Male	304 (36)	21	30	7632 (39)	29	36
Female	536 (64)	19	26	12 116 (61)	26	32
Age (years)						
18–39	361 (43)	18	27	4983 (25)	24	32
40–49	209 (25)	20	28	4873 (25)	27	34
50–59	233 (28)	21	26	5133 (26)	28	34
59–98	37 (4)	19	23	4759 (24)	29	36
Smoking						
0–20 pack-years	381 (45)	19	30	7435 (38)	28	37
>20 pack-years	459 (55)	19	25	12 313 (62)	26	32
Fagerström 1–4 points	227 (27)	23	33	7579 (38)	32	39
Fagerström 5–10 points	613 (73)	178	25	12 169 (62)	24	30
0 to <10 cigarettes per day	60 (7)	18	27	1755 (9)	34	43
10 to <20	252 (30)	27	39	6961 (35)	29	36
20 to <30	360 (43)	17	24	8173 (41)	25	32
30 to <40	111 (13)	14	18	1996 (10)	22	29
40+	57 (7)	14	16	863 (4)	22	28
Compliance with programme						
Compliant	396 (47)	32	40	11 774 (60)	36	43
Not compliant	426 (51)	8	13	7580 (38)	13	18
Missing information	18 (2)	6	10	394 (2)	29	38
Living with a smoker						
Yes	292 (35)	20	28	6747 (34)	26	32
No	545 (65)	19	26	12 848 (65)	27	35
Missing information	3 (0)			158 (1)		
Attempts to quit						
Never attempted to quit	418 (50)	18	25	7633 (39)	26	33
1–3	350 (42)	20	28	9880 (50)	27	33
>3 attempts	68 (8)	25	36	1858 (9)	31	38
Missing information	4 (0)			377 (2)	23	32
Professional recommendation						
Yes	531 (63)	18	24	10 927 (55)	26	32
No	309 (37)	21	32	8821 (45)	29	36
Education						
Low level	371 (44)	16	24	5367 (27)	23	30
High level	446 (53)	23	30	13 636 (69)	29	36
Missing information	23 (3)	9	13	745 (4)	22	28

Continued

Table 3 Continued

	Unemployed			Not unemployed		
	Characteristics n (%)	Continuous abstinence (%)		Characteristics n (%)	Continuous abstinence (%)	
		All	Responders		All	Responders
Unemployment						
Unemployed	840 (100)	19	27			
Not unemployed				19 233 (97)	27	34
Missing information				515 (3)	23	31

was between 18% and 23% for all other socio-demographic, smoking- and intervention-related variables.

Overall, 34% (5503 of 16377 patients) reported 6 months of continuous abstinence. Continuous abstinence was 27%, when all non-responders were considered to be smokers. Of the 16377 responding to follow-up, 27% had a lower level of education and 4% were unemployed (figure 1). The characteristics of all of the patients with respect to unemployment or level of education are shown in tables 2 and 3.

Continuous abstinence was significantly lower for the patients with a lower education level (30%) compared with those with a higher education level (35%,  $p<0.001$ ) in those responding (of all registered: 23% vs 28%, table 2). Continuous abstinence was also significantly lower for the unemployed patients (27%) compared with those who were employed (34%,  $p<0.001$ ), corresponding to 19% versus 27% of all registered (table 3).

The overall difference in continuous abstinence between disadvantaged and non-disadvantaged patients was 5% (with respect to education) and 7% (with respect to unemployment). The difference was up to 11% (with respect to high vs low education in patients with three or more quit attempts) or 15% with respect to unemployment (vs non-unemployed) in patients receiving free medication for <5 weeks and 12% in the patients 59 years and older as well as in those smoking <10 cigarettes per day (16%) or more than 40 cigarettes per day (12%). Comparing disadvantaged patients with non-disadvantaged patients, the most striking difference was observed in respect to employment in the hospital setting: continuous abstinence was 14% higher in non-unemployed patients compared with unemployed patients.

The characteristics and percentage of the disadvantaged patients with continuous abstinence are shown in tables 2 and 3. The results of the univariate and multivariable analyses for the 6-month continuous abstinence rate are shown in table 1. The final model revealed that the lower Fagerström Test for Nicotine Dependence Score<sup>21</sup> (per point) and compliance with the programme were the only consistent predictors associated with continuous abstinence in both groups of disadvantaged patients.

For patients with the lower educational level, the variable 'individual format' of the GSP was a predictor of success in smoking cessation (OR=1.31, 95% CI 1.05 to 1.63), but for unemployed patients, it did not remain in the final model.

In the group of patients with a lower educational level, male gender or not having received a recommendation to quit by a health professional were also predictors for continuous abstinence.

## DISCUSSION

Among disadvantaged smokers participating in the Danish GSP for smoking cessation, we can report relatively high continuous abstinence rates of those responding (27%–30%) and 19%–23% of all registered for treatment. However, this is still 5%–7%

lower than non-disadvantaged smokers. In absolute terms, there would be eight extra quitters per year if the programme was as effective for the unemployed group as it was for the employed smokers and 46 extra quitters per year for the patients with a lower level of education. Nine of 10 patients received group GSP, but continuous abstinence was somewhat higher among the one-tenth of patients who participated in a programme with an individual format, regardless of being disadvantaged. No other potentially modifiable component of greater effectiveness for disadvantaged patients was identified. It was impossible to draw firm conclusions about the effect of payment for medication, as there were too few patients in the subgroup that received free medication for <5 weeks or longer. In nearly all subgroups, there was a consistent and varying lower rate of continuous abstinence in disadvantaged patients. Interestingly, in the hospital setting, continuous abstinence was 14% lower in unemployed patients compared with non-unemployed patients.

The proportion of patients not responding to follow-up was moderate, and the sensitivity analysis revealed relatively robust findings. It should be emphasised again that the Russell criteria<sup>23</sup> were not applicable in this registry-based cohort study.

To our knowledge, continuous abstinence of disadvantaged patients, with regard to the format, the setting, the region and payment modality, have not been reported in randomised clinical trial or in cohort studies. Most of the evidence about smoking cessation derives from randomised trials, but it is regrettable that up to six of 10 patients with nicotine dependence were not eligible for these studies because they fulfilled at least one exclusion criteria.<sup>12</sup> In contrast to studies applying stricter inclusion criteria,<sup>11 12 24 25</sup> our study included patients aged 18 years or older undergoing the GSP in Denmark, regardless of smoking severity, motivation to quit, comorbidity or whether a quit date were set.

In the UK, smoking cessation services have been successfully implemented in deprived areas, but low long-term cessation rates in the range of 5%–11% were reported, even though these studies included quitters at 4 weeks, exclusively.<sup>2 6 24</sup> In the UK, only 3% of all patients were in group programmes,<sup>9 24–26</sup> which had a higher success rate.<sup>9 24 26</sup> Many obstacles to attendance have been identified in the UK, for example, difficulties in finding adequate transport in rural areas or reported time constraints. All of this does not seem to play a major role for Danish patients. Patients who participated in a programme with an individual format showed a favourable outcome regardless of being disadvantaged. It remains unclear whether this finding is primarily related to patient preferences or staff competencies. Those 10%–12% entering the individual format might be a selected subgroup benefiting substantially from the individualised approach. Other factors not sufficiently addressed, such as comorbidity, patient resources or motivation or the patient's ability to recall events in the past, such as a health professional's recommendation to quit, might be also important in the context of continuous abstinence after the programme.

**Table 4** Patient characteristics with respect to response

	All	Non-responding (%)	Responding (%)
N	20 588	4211 (100%)	16 377 (100%)
Setting			
Hospital/midwifery	2299	10	11
Pharmacies	5214	25	25
Municipality/county	12 891	64	62
Other and missing information	184	0	1
Format			
Individual	1841	9	9
Group	18 642	90	91
Other and missing information	105	0	1
Medication for free			
No free medication	10 913	50	54
Free medication for a few days	7785	41	37
Free medication for <5 weeks	1588	8	8
Free medication for 5 weeks	302	1	1
Region			
Living in the capital	8419	45	40
Living in other regions	12 169	55	60
Midtjylland	4067	17	20
Nordjylland	814	4	4
Sjælland	3043	15	15
Syddanmark	4245	19	21
Gender			
Male	7936	39	39
Female	12 652	61	61
Age (years)			
18–39	5344	32	24
40–49	5082	25	25
50–59	5366	24	27
59–98	4796	20	24
Smoking			
0–20 pack-years	7816	43	37
>20 pack-years	12 772	57	63
Fagerström 1–4 points	7806	36	38
Fagerström 5–10 points	12 782	64	62
0 to <10 cigarettes per day	1815	9	9
10 to <20	7213	34	35
20 to <30	8533	41	42
30 to <40	2107	11	10
40+	920	5	4
Compliance with programme			
Compliant	12 170	47	62
Not compliant	8006	51	36
Missing information	412	2	2
Living with a smoker			
Yes	7039	33	35
No	13 393	66	65
Missing information	156	1	1
Attempts to quit			
Never attempted to quit	8051	40	39
1–3 attempts	10 230	49	50
>3 attempts	1926	9	10
Missing information	381	2	2
Professional recommendation			
Yes	11 458	54	56
No	9130	46	44
Education			
Low level	5738	32	27
High level	14 082	64	70
Missing information	768	4	4
Unemployment			
Unemployed	840	6	4
Not unemployed	19 233	91	94
Missing information	515	3	2

### What is already known on this subject

Lower socioeconomic groups have higher smoking rates and less often access to preventive health services such as smoking cessation intervention programmes.

### What this study adds

The GSP is effective in disadvantaged patients almost to the same degree as in non-disadvantaged patients. Minor improvements may be achieved through modifications of the programme that is a change from a group to an individual format.

This is a real-life nationwide evaluation of continuous abstinence in disadvantaged smokers undergoing the GSP. It has been estimated that the Smoking Cessation Database includes about 90% of all registered smoking cessation activities in Denmark, and more than 5% of all Danish smokers have been registered in the database to date.<sup>27</sup>

The proportion of unemployed patients included in our study (4%) can be considered representative for Denmark (3%–6%),<sup>28</sup> suggesting that they were sufficiently reached.

However, patients with a lower educational level seemed to have been under-represented: in our study, there were 27% compared with 37% in the Danish population.<sup>29</sup>

The definition of disadvantaged in the present study can only be seen in the context of Danish society, and caution is needed if conclusions are drawn for societies with a different social system to that of Denmark. The discrepancies between disadvantaged and higher social classes might be more pronounced in other societies, as the degree of social consensus is relatively high in Denmark. One has to keep in mind that all outcome data rely on self-reporting, thus estimates of continuous abstinence may be too high. The difference between co-validated and self-reported continuous abstinence is reported to be between 3% and 6%.<sup>8 24 25 30</sup>

It seems that the GSP might overcome at least, to some degree, the inequity related to disadvantaged smokers. The major implication for clinicians would be to refer more disadvantaged patients to the GSPs. It is important for policy makers to ensure that disadvantaged patients do get access to these successful programmes. Promoting individual interventions among those with low education may increase the effectiveness of GSP. Future research should focus on how to bring more patients into smoking cessation intervention programmes. The dominating predictor for continuous abstinence was compliance for the disadvantaged as well as for the non-disadvantaged patient; however, the direction of causality for compliance cannot be addressed by this approach. Future research should also address the improvement of compliance and the role of pharmacies in the care of disadvantaged smokers.

**Contributors** HT and TN were responsible for the study concept and design. Staff from the smoking cessation units in Denmark collected the data. MR coordinated the data collection and processing. TN, BLH, NG and HT did the statistical analyses. All authors contributed to the interpretation of the analyses and the results. TN and HT wrote the article. BLH, MR and NG revised it. All authors approved the final edition. All authors had full access to all the data (including statistical reports and tables) in the



## Research paper

study and can take responsibility for the integrity of the data and the accuracy of the data analysis. TN and HT are guarantors for the study.

**Funding** Funding was provided by the Danish National Board of Health and the Danish Ministry of Interior and Health. The funders finance the daily function of the Danish Smoking Cessation Database. The funders have not been involved in the research project.

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** This project was approved by the Danish Data Protection Agency (J.-Nr. 2010-41-5463) and registered at the Scientific Ethical Committee (Prot.-Nr. H-C-FSP-2010-049). All patients gave written informed consent.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Technical appendix is available on <http://www.rygestopbasen.dk>. Participants gave no informed consent for data sharing.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

## REFERENCES

- Browning KK**, Ferketich AK, Salsberry PJ, *et al*. Socioeconomic disparity in provider-delivered assistance to quit smoking. *Nicotine Tob Res* 2008;**10**:55–61.
- Hiscock R**, Judge K, Bauld L. Social inequalities in quitting smoking: what factors mediate the relationship between socioeconomic position and smoking cessation? *J Public Health (Oxf)* 2010;**33**:39–47.
- World Health Organization**. *WHO Report On The Global Tobacco Epidemic, 2009: Implementing Smoke-Free Environments*. 2009. <http://www.who.int/tobacco/mpower/en/>
- Amos A**, Amos A, Bauld L, *et al*. 2011. *Tobacco Control, Inequalities In Health And Action At A Local Level*. York: Public Health Research Consortium, 2011.
- Cahill K**, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev* 2010;(4):CD006103.
- Kotz D**, West R. Explaining the social gradient in smoking cessation: it's not in the trying, but in the succeeding. *Tob Control* 2009;**18**:43–6.
- Lancaster T**, Stead LF. Individual behavioural counselling for smoking cessation. *Cochrane Database Syst Rev* 2005;(2):CD001292.
- Lumley J**, Chamberlain C, Dowswell T, *et al*. Interventions for promoting smoking cessation during pregnancy. *Cochrane Database Syst Rev* 2009;(3):CD001055.
- Stead LF**, Lancaster T. Group behaviour therapy programmes for smoking cessation. *Cochrane Database Syst Rev* 2005;(2):CD001007.
- Stead LF**, Bergson G, Lancaster T. Physician advice for smoking cessation. *Cochrane Database Syst Rev* 2008;(2):CD000165.
- Prochaska JO**, Evers KE, Prochaska JM, *et al*. Efficacy and effectiveness trials: examples from smoking cessation and bullying prevention. *J Health Psychol* 2007;**12**:170–8.
- LeStrat Y**, Rehm J, LeFoll B. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. *Tob Control* 2011;**20**:338–43.
- Kjaer NT**, Ewald T, Rasmussen M, *et al*. The effectiveness of nationally implemented smoking interventions in Denmark. *Prev Med* 2007;**45**:12–14.
- Olsen KR**, Bilde L, Juhl HH, *et al*. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish smoking cessation database. *Eur J Health Econ* 2006;**7**:255–64.
- Borglykke A**, Pisinger C, Jorgensen T, *et al*. The effectiveness of smoking cessation groups offered to hospitalised patients with symptoms of exacerbations of chronic obstructive pulmonary disease (COPD). *Clin Respir J* 2008;**2**:158–65.
- Moller AM**, Villebro N, Pedersen T, *et al*. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. *Lancet* 2002;**359**:114–17.
- Tonnesen H**. Surgery and smoking at first and second hand: time to act. *Anesthesiology* 2011;**115**:1–3.
- Bauld L**, Chesterman J, Ferguson J, *et al*. A comparison of the effectiveness of group-based and pharmacy-led smoking cessation treatment in Glasgow. *Addiction* 2009;**104**:308–16.
- Cahill K**, Perera R. Competitions and incentives for smoking cessation. *Cochrane Database Syst Rev* 2008;(3):CD004307.
- Danish Cancer Society**. Manual for individual smoking cessation intervention. In: Lind M, ed. *Manual For Smoking Cessation Intervention In Groups*. 2nd edn. Copenhagen: Internet Communication, 2008. [http://www.cancer.dk/fagfolk/forebyggelse/rygning/Rygestoppraadgivere/grundkurser\\_til\\_rygestoppraadgivere/](http://www.cancer.dk/fagfolk/forebyggelse/rygning/Rygestoppraadgivere/grundkurser_til_rygestoppraadgivere/) (accessed 11 Nov 2011).
- Heatherton TF**, Kozlowski LT, Frecker RC, *et al*. The Fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. *Br J Addict* 1991;**86**:1119–27.
- Von Elm E**, Altman DG, Egger M, *et al*. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007;**335**:806–8.
- West R**, Hajek P, Stead L, *et al*. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction* 2005;**100**:299–303.
- Ferguson J**, Bauld L, Chesterman J, *et al*. The English smoking treatment services: one-year outcomes. *Addiction* 2005;**100**(Suppl 2):59–69.
- Judge K**, Bauld L, Chesterman J, *et al*. The English smoking treatment services: short-term outcomes. *Addiction* 2005;**100**(Suppl 2):46–58.
- Bauld L**, Bell K, McCullough L, *et al*. The effectiveness of NHS smoking cessation services: a systematic review. *J Public Health* 2010;**32**:71–82.
- OECD**. *OECD Health data 2010. How Does Denmark Compare*. 2011. <http://www.oecd.org/dataoecd/46/32/38979778.pdf>
- Statistics Denmark**. *Seasonally Adjusted Figures By Seasonal Adjustment And Actual Figures, Region And Time*. 2011. [http://www.dst.dk/HomeUK/Statistics/focus\\_on/focus\\_on\\_show.aspx?sci=203](http://www.dst.dk/HomeUK/Statistics/focus_on/focus_on_show.aspx?sci=203)
- Statistics Denmark**. *Educational Attainment Of The Population By Age, Education And Time*. 2011. [http://www.dst.dk/HomeUK/Statistics/focus\\_on/focus\\_on\\_show.aspx?sci=569](http://www.dst.dk/HomeUK/Statistics/focus_on/focus_on_show.aspx?sci=569)
- Pisinger C**, Vestbo J, Borch-Johnsen K, *et al*. Smoking cessation intervention in a large randomised population-based study. The inter99 study. *Prev Med* 2005;**40**:285–92.



## The Gold Standard Programme: smoking cessation interventions for disadvantaged smokers are effective in a real-life setting

Tim Neumann, Mette Rasmussen, Nermin Ghith, et al.

*Tob Control* 2013 22: e9 originally published online June 16, 2012  
doi: [10.1136/tobaccocontrol-2011-050194](https://doi.org/10.1136/tobaccocontrol-2011-050194)

---

Updated information and services can be found at:  
<http://tobaccocontrol.bmj.com/content/22/6/e9.full.html>

---

*These include:*

### References

This article cites 18 articles, 5 of which can be accessed free at:  
<http://tobaccocontrol.bmj.com/content/22/6/e9.full.html#ref-list-1>

Article cited in:

<http://tobaccocontrol.bmj.com/content/22/6/e9.full.html#related-urls>

### Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:  
<http://creativecommons.org/licenses/by-nc/3.0/>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Topic Collections

Articles on similar topics can be found in the following collections  
[Open access](#) (153 articles)

---

### Notes

---

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>